In 2014, Congress passed the Protecting Access to Medicare Act (PAMA) to reform payment to clinical laboratories under the Clinical Laboratory Fee Schedule (CLFS). CMS's flawed implementation led to rates that fail to reflect private payer rates as intended, years of payment cuts, and a lack of recognition of rising inflation. Without Congressional action, more…
In 2014, Congress passed the Protecting Access to Medicare Act (PAMA) to reform payment to clinical laboratories under the Clinical Laboratory Fee Schedule (CLFS). CMS's flawed implementation led to rates that fail to reflect private payer rates as intended, years of payment cuts, and a lack of recognition of rising inflation. Without Congressional action, more cuts will begin on January 1, 2025. ACLA urges Congress to enact long-term PAMA reform to protect access to quality laboratory diagnostics and services.
-
Preventive Screenings and Routine Testing Are Essential for Protecting Seniors’ Health
With Medicare reimbursement for nearly 600 laboratory tests scheduled for significant cuts in a matter of weeks, 56 million seniors are at risk of losing access to ... Read More -
For 56 Million Seniors, New Cuts to Lab Tests Makes the Road to Better Health Much Harder
Millions of seniors weathered the worst of the pandemic – the uncertainty of COVID-19, the disruptions to family life and the ongoing risks to their ... Read More -
Seniors’ return to health could be jeopardized by upcoming lab cuts
Over the past two years, seniors have had to be extra vigilant when it comes to protecting their health, especially those with existing health issues ... Read More -
ACLA Statement on MedPAC Report
WASHINGTON, D.C.— Following the release of MedPAC’s June report, ACLA President Julie Khani issued the following statement: “Recognizing the flawed implementation of the 2014 Protecting Access to ... Read More -
ACLA Files Notice of Appeal in ACLA v. Becerra
Washington, D.C. – The American Clinical Laboratory Association (ACLA) today filed a notice of appeal in its lawsuit against the U.S. Department of Health and Human ... Read More -
ACLA v. Becerra: Frequently Asked Questions
What is ACLA’s response to the court’s recent dismissal of the lawsuit? On March 30, 2021, the district court for the District of Columbia issued ... Read More -
ACLA Comments on MedPAC CLFS Session – September 2020
-
LAB Act Co-Sponsors Letter to CMS
-
Government’s Brief in ACLA v. Azar
-
ACLA’s Motion for Summary Judgment in ACLA v. Azar